ctDx ALK passes CLIA test with flying colours.

If you were at AACR, and into liquid biopsies, you probably came across Resolution Bio. They’re well on their way to bringing some great technology to the front lines. Specifically, ctDx ALK, a blood-based liquid biopsy for an ALK-gene fusion driver mutation found in non-small cell lung carcinoma (NSCLC). The company just announced its successful results from their CLIA validation for ctDx ALK: “no deficiencies” – the highest assessment you can get from the CLIA authority.

Resolution Bio have some very ambitious plans and are already turning some heads. Getting the CLIA certification is going to be a big step forward in proving that they’re platform can deliver. For now, it means that any accredited molecular lab, with the right expertise, can use this assay and start helping NSCLC patients right away.

“Resolution Bio is committed to the highest operational and quality standards. Our CLIA certification is an important regulatory milestone and demonstrates our ability to create and validate clinically-relevant, blood-based tumor genotyping technologies to support our ongoing partnerships with the oncology and pharmaceutical community.” commented Resolution Bio, CEO, Mark Li.

The company are currently validating additional assays and working on some exciting collaborations. They’ll be one to keep an eye on for 2015.